サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1475889

バイオシミラーインスリン市場：地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ）：世界の産業分析、規模、シェア、成長、動向、予測、2024-2031年

Biosimilar Insulin Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日: | 発行: Persistence Market Research | ページ情報: 英文 250 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.16円
バイオシミラーインスリン市場：地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ）：世界の産業分析、規模、シェア、成長、動向、予測、2024-2031年
出版日: 2024年04月30日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社は、世界のバイオシミラーインスリン市場を包括的に分析し、市場力学、主要促進要因・課題、新たな動向を調査しています。本レポートは、2024年から2031年までの予測市場軌跡の詳細な概要を提供し、バイオシミラーインスリン産業の利害関係者や意思決定者に重要な洞察を提供します。

世界のバイオシミラーインスリン市場の収益推計は、2024年末時点で19億米ドルに達し、世界市場のCAGRは14.9%で急増し、2031年末には50億米ドルに達すると推定されます。

主な洞察

  • 推定市場価値（2024年）：19億米ドル
  • 予測市場価値（2031年）：50億米ドル
  • 世界市場成長率（CAGR 2024年～2031年）：14.9%

バイオシミラーインスリン市場-調査範囲：

世界の糖尿病有病率の増加は、バイオシミラーインスリン需要を牽引する主要因の一つです。インスリン療法を必要とする患者が増加しており、バイオシミラーはブランドインスリン製剤に代わる費用対効果の高い選択肢を提供しています。政府やヘルスケアプロバイダーは、特にインスリンへのアクセスが限られている地域において、医療費削減のためにバイオシミラーの採用を推進しています。この動向は、バイオシミラー製品の承認・販売を優遇する規制政策にも支えられています。

市場成長の促進要因：

バイオシミラーインスリン市場成長の主な促進要因としては、糖尿病、特に2型糖尿病の有病率の増加と、より手頃な価格のインスリン製剤に対する需要の高まりが挙げられます。ブランドインスリンのコスト上昇により、より安価な代替品へのニーズが高まっており、バイオシミラーインスリンは患者やヘルスケアシステムにとって魅力的な選択肢となっています。さらに、バイオシミラーの承認と市場参入を促進するために規制の枠組みが進化しており、市場の成長をさらに後押ししています。

市場抑制要因：

その可能性にもかかわらず、バイオシミラーインスリン市場はいくつかの課題に直面しています。主な懸念事項の1つは、医療従事者が既存のブランドインスリン製剤からバイオシミラー製剤への切り替えに消極的であることです。このような躊躇は、多くの場合、バイオシミラーの有効性と安全性が先発品と比較して不確実であることに起因しています。さらに、バイオシミラーインスリンの薬事承認プロセスは複雑でコストがかかるため、市場参入の障壁となっています。知的財産の問題や特許訴訟も市場拡大のリスクとなります。

市場機会：

バイオシミラーインスリン市場には、成長と拡大の大きな機会があります。インスリン製剤の特許が切れると、バイオシミラー製剤が市場に参入し、競争が激化して価格が下がる可能性があります。また、製薬企業とヘルスケアプロバイダーとの提携により、バイオシミラーの普及が促進される可能性があります。個別化医療と患者中心の医療への注目が高まることは、バイオシミラーインスリンを柔軟で手頃な治療選択肢として普及させる好機となります。さらに、バイオシミラーの利点に関する認識と教育の向上は、医療従事者と患者の抵抗感を克服するのに役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/分類
  • 市場の定義/範囲/制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 重要成功要因

  • 主要製品のUSP/機能分析
  • 規制シナリオ
  • メーカーの主なプロモーション戦略
  • 最近の製品リリース
  • バリューチェーン分析
  • 地域別製品採用分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因-関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • 2023年の市場シナリオ
  • COVID-19と影響分析
    • 製品別
    • 流通チャネル別
    • 地域別

第7章 世界のバイオシミラーインスリン市場の需要分析（金額）

  • 過去の市場（金額）分析、2019-2023年
  • 現在および将来の市場（金額）予測、2024～2031年

第8章 世界のバイオシミラーインスリン市場-価格分析

  • 製品別の地域別価格分析
  • 世界平均価格分析ベンチマーク
  • 価格の内訳
    • メーカーレベルの価格設定
    • ディストリビューターレベルの価格設定
  • 価格設定の前提条件

第9章 世界のバイオシミラーインスリン市場分析、製品別

  • イントロダクション/主な調査結果
  • 過去の市場規模（金額）分析、2019-2023年
  • 現在および将来の市場規模（金額）分析と予測、製品別、2024-2031年
    • インスリングラルギン
    • インスリンアナログ
    • その他
  • 製品別市場魅力度分析

第10章 世界のバイオシミラーインスリン市場分析、流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模（金額）分析、2019-2023年
  • 現在および将来の市場規模（金額）分析と予測、製品別、2024-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場魅力度分析

第11章 世界のバイオシミラーインスリン市場分析、地域別

  • イントロダクション
  • 過去の市場規模（金額）分析、2019-2023年
  • 現在および将来の市場規模（金額）分析と予測、製品別、2024-2031年
    • 北米
    • ラテンアメリカ
    • 欧州
    • アジア太平洋（APAC）
    • 中東およびアフリカ（MEA）
  • 地域別市場魅力度分析

第12章 北米のバイオシミラーインスリン市場分析

第13章 ラテンアメリカのバイオシミラーインスリン市場分析

第14章 欧州のバイオシミラーインスリン市場分析

第15章 アジア太平洋（APAC）のバイオシミラーインスリン市場分析

第16章 中東およびアフリカ（MEA）のバイオシミラーインスリン市場分析

第17章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第18章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Biocon
    • Eli Lilly and Company
    • Sanofi
    • BGP Pharma
    • Aspen
    • Mylan（Viatris）

第19章 使用される前提条件と頭字語

第20章 調査手法

目次
Product Code: PMRREP11674

Persistence Market Research presents a comprehensive analysis of the global Biosimilar Insulin Market, examining the market dynamics, key drivers, challenges, and emerging trends. This report offers a detailed overview of the projected market trajectory from 2024 through 2031, providing critical insights for stakeholders and decision-makers in the biosimilar insulin industry.

Revenue from the global biosimilar insulin market reached US$ 1.9 Bn at the end of 2024, with the global market estimated to surge ahead at a value CAGR of 14.9% to reach US$ 5 Bn by the end of 2031.

Key Insights:

  • Estimated Market Value (2024): USD 1.9 Billion
  • Projected Market Value (2031): USD 5 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 14.9%

Biosimilar Insulin Market - Report Scope:

The growing prevalence of diabetes globally is one of the primary factors driving the demand for biosimilar insulin. An increasing number of patients require insulin therapy, and biosimilars offer a cost-effective alternative to branded insulin products. Governments and healthcare providers are promoting biosimilar adoption to reduce healthcare expenditure, especially in regions with limited access to insulin. This trend is further supported by regulatory policies favoring the approval and marketing of biosimilar products.

Market Growth Drivers:

The key drivers of growth in the biosimilar insulin market include the increasing prevalence of diabetes, especially type 2 diabetes, and the growing demand for more affordable insulin options. The rising cost of branded insulin has created a need for cheaper alternatives, making biosimilar insulin an attractive choice for patients and healthcare systems. Additionally, regulatory frameworks are evolving to facilitate the approval and market entry of biosimilars, further boosting market growth.

Market Restraints:

Despite its potential, the biosimilar insulin market faces several challenges. One of the primary concerns is the reluctance among healthcare professionals to switch from established branded insulin products to biosimilars. This hesitancy is often due to uncertainty about the efficacy and safety of biosimilars compared to their branded counterparts. Furthermore, the regulatory approval process for biosimilar insulin can be complex and costly, creating barriers for market entry. Intellectual property issues and patent litigation also pose risks to market expansion.

Market Opportunities:

The biosimilar insulin market offers significant opportunities for growth and expansion. As more insulin patents expire, new biosimilar products can enter the market, increasing competition and driving down prices. Additionally, partnerships between pharmaceutical companies and healthcare providers can facilitate wider adoption of biosimilars. The growing focus on personalized medicine and patient-centric care provides an opportunity to promote biosimilar insulin as a flexible and affordable treatment option. Furthermore, increased awareness and education about the benefits of biosimilars can help overcome resistance among healthcare professionals and patients.

Key Questions Addressed in the Report:

  • What is the Expected Value CAGR of the Biosimilar Insulin Market from 2024 to 2031?
  • What are the Primary Drivers for the Growth of the Biosimilar Insulin Market?
  • Which Regions Offer the Most Significant Growth Opportunities for the Biosimilar Insulin Market?
  • Who are the Key Players in the Global Biosimilar Insulin Market?
  • What are the Major Challenges Faced by the Biosimilar Insulin Market?

Competitive Landscape and Business Strategies:

Leading players in the biosimilar insulin market include Mylan N.V., Biocon Limited, Sanofi, and Eli Lilly and Company. These companies focus on product innovation, strategic partnerships, and market expansion to maintain a competitive edge. Strategies include expanding manufacturing capabilities, investing in R&D for new biosimilar products, and entering strategic alliances with other pharmaceutical companies to broaden market reach. Additionally, collaborations with healthcare providers and insurance companies help drive biosimilar adoption and increase market penetration.

Key Companies Profiled:

  • Biocon
  • Eli Lilly and Company
  • Sanofi
  • BGP Pharma
  • Aspen
  • Mylan (Viatris)

Biosimilar Insulin Market Segmentation:

Biosimilar Insulin Market by Product:

  • Insulin Glargine
  • Insulin Analog
  • Others

Biosimilar Insulin Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Biosimilar Insulin Market by Region:

  • North America Biosimilar Insulin Market
  • Latin America Biosimilar Insulin Market
  • Europe Biosimilar Insulin Market
  • APAC Biosimilar Insulin Market
  • Middle East & Africa Biosimilar Insulin Market

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion And Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Key Products USP/Feature Analysis
  • 4.2. Regulatory Scenario
  • 4.3. Key Promotional Strategies By Manufacturers
  • 4.4. Recent Product Launches
  • 4.5. Value Chain Analysis
  • 4.6. Product Adoption Analysis by Region

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Industry Outlook
    • 5.1.3. Parent Market Analysis (Insulin Market)
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growing Prevalence Of Diabetes
    • 5.2.2. Increasing Research and Development Activities
    • 5.2.3. New Product Launches
    • 5.2.4. Increasing Number Of Clinical Trials
    • 5.2.5. Patent Expiry for Insulin
    • 5.2.6. Growing Geriatric Population
    • 5.2.7. Increasing Insulin Manufacturers
    • 5.2.8. Requirement of Cost-Efficient Products
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. 2023 Market Scenario
  • 6.2. COVID-19 and Impact Analysis
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Region

7. Global Biosimilar Insulin Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Biosimilar Insulin Market - Pricing Analysis

  • 8.1. Regional Pricing Analysis By Product
  • 8.2. Global Average Pricing Analysis Benchmark
  • 8.3. Pricing Break-up
    • 8.3.1. Manufacturer Level Pricing
    • 8.3.2. Distributor Level Pricing
  • 8.4. Pricing Assumptions

9. Global Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031, By Product

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2024-2031
    • 9.3.1. Insulin Glargine
    • 9.3.2. Insulin Analog
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis By Product

10. Global Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. Asia Pacific (APAC)
    • 11.3.5. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

  • 12.1. Introduction
  • 12.2. Pricing Analysis
  • 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 12.4.1. By Country
      • 12.4.1.1. U.S.
      • 12.4.1.2. Canada
    • 12.4.2. By Product
    • 12.4.3. By Distribution Channel
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Country
    • 12.5.2. By Product
    • 12.5.3. By Distribution Channel
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Biosimilar Insulin Market
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Product
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Canada Biosimilar Insulin Market
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Product
        • 12.8.2.2.2. By Distribution Channel

13. Latin America Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 13.4.1. By Country
      • 13.4.1.1. Brazil
      • 13.4.1.2. Argentina
      • 13.4.1.3. Mexico
      • 13.4.1.4. Rest of Latin America
    • 13.4.2. By Product
    • 13.4.3. By Distribution Channel
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Product
    • 13.5.3. By Distribution Channel
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Brazil Biosimilar Insulin Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Argentina Biosimilar Insulin Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. Mexico Biosimilar Insulin Market
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Product
        • 13.8.3.2.2. By Distribution Channel

14. Europe Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 14.4.1. By Country
      • 14.4.1.1. Germany
      • 14.4.1.2. Italy
      • 14.4.1.3. France
      • 14.4.1.4. U.K.
      • 14.4.1.5. Spain
      • 14.4.1.6. BENELUX
      • 14.4.1.7. Nordic Countries
      • 14.4.1.8. Russia
      • 14.4.1.9. Rest of Europe
    • 14.4.2. By Product
    • 14.4.3. By Distribution Channel
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Product
    • 14.5.3. By Distribution Channel
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Biosimilar Insulin Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. France Biosimilar Insulin Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. Italy Biosimilar Insulin Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Distribution Channel
    • 14.8.4. Spain Biosimilar Insulin Market
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.4.2.1. By Product
        • 14.8.4.2.2. By Distribution Channel
    • 14.8.5. U.K. Biosimilar Insulin Market
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.5.2.1. By Product
        • 14.8.5.2.2. By Distribution Channel
    • 14.8.6. BENULUX Biosimilar Insulin Market
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.6.2.1. By Product
        • 14.8.6.2.2. By Distribution Channel
    • 14.8.7. Nordic Countries Biosimilar Insulin Market
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.7.2.1. By Product
        • 14.8.7.2.2. By Distribution Channel
    • 14.8.8. Russia Biosimilar Insulin Market
      • 14.8.8.1. Introduction
      • 14.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.8.2.1. By Product
        • 14.8.8.2.2. By Distribution Channel

15. Asia Pacific (APAC) Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Pricing Analysis
  • 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 15.4.1. By Country
      • 15.4.1.1. China
      • 15.4.1.2. Japan
      • 15.4.1.3. India
      • 15.4.1.4. Australia
      • 15.4.1.5. New Zealand
    • 15.4.2. By Product
    • 15.4.3. By Distribution Channel
  • 15.5. Market Attractiveness Analysis
    • 15.5.1. By Country
    • 15.5.2. By Product
    • 15.5.3. By Distribution Channel
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Biosimilar Insulin Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Japan Biosimilar Insulin Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. India Biosimilar Insulin Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Australia Biosimilar Insulin Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Distribution Channel
    • 15.8.5. New Zealand Biosimilar Insulin Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Distribution Channel

16. Middle East and Africa (MEA) Biosimilar Insulin Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Pricing Analysis
  • 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 16.4.1. By Country
      • 16.4.1.1. GCC Countries
      • 16.4.1.2. Israel
      • 16.4.1.3. Turkey
      • 16.4.1.4. Egypt
      • 16.4.1.5. North Africa
      • 16.4.1.6. South Africa
      • 16.4.1.7. Rest of Middle East and Africa
    • 16.4.2. By Product
    • 16.4.3. By Distribution Channel
  • 16.5. Market Attractiveness Analysis
    • 16.5.1. By Country
    • 16.5.2. By Product
    • 16.5.3. By Distribution Channel
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. GCC Countries Biosimilar Insulin Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. Israel Biosimilar Insulin Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Distribution Channel
    • 16.8.3. Turkey Biosimilar Insulin Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Distribution Channel
    • 16.8.4. Egypt Biosimilar Insulin Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Product
        • 16.8.4.2.2. By Distribution Channel
    • 16.8.5. North Africa Biosimilar Insulin Market
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Product
        • 16.8.5.2.2. By Distribution Channel
    • 16.8.6. South Africa Biosimilar Insulin Market
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Product
        • 16.8.6.2.2. By Distribution Channel

17. Market Structure Analysis

  • 17.1. Market Analysis by Tier of Companies
  • 17.2. Market Share Analysis of Top Players
  • 17.3. Market Presence Analysis
    • 17.3.1. Regional footprint of Players
    • 17.3.2. Platform Type foot print by Players
    • 17.3.3. Channel Foot Print by Players

18. Competition Analysis

  • 18.1. Competition Dashboard
  • 18.2. Competition Benchmarking
  • 18.3. Competition Deep Dive
    • 18.3.1. Biocon
      • 18.3.1.1. Overview
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Key Financials
      • 18.3.1.4. Geographical Footprint
      • 18.3.1.5. SWOT Analysis
      • 18.3.1.6. Key Developments
      • 18.3.1.7. Strategy Overview
        • 18.3.1.7.1. Channel Strategy
        • 18.3.1.7.2. Marketing Strategy
        • 18.3.1.7.3. Product Strategy
    • 18.3.2. Eli Lilly and Company
      • 18.3.2.1. Overview
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Key Financials
      • 18.3.2.4. Geographical Footprint
      • 18.3.2.5. SWOT Analysis
      • 18.3.2.6. Key Developments
      • 18.3.2.7. Strategy Overview
        • 18.3.2.7.1. Channel Strategy
        • 18.3.2.7.2. Marketing Strategy
        • 18.3.2.7.3. Product Strategy
    • 18.3.3. Sanofi
      • 18.3.3.1. Overview
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Key Financials
      • 18.3.3.4. Geographical Footprint
      • 18.3.3.5. SWOT Analysis
      • 18.3.3.6. Key Developments
      • 18.3.3.7. Strategy Overview
        • 18.3.3.7.1. Channel Strategy
        • 18.3.3.7.2. Marketing Strategy
        • 18.3.3.7.3. Product Strategy
    • 18.3.4. BGP Pharma
      • 18.3.4.1. Overview
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Key Financials
      • 18.3.4.4. Geographical Footprint
      • 18.3.4.5. SWOT Analysis
      • 18.3.4.6. Key Developments
      • 18.3.4.7. Strategy Overview
        • 18.3.4.7.1. Channel Strategy
        • 18.3.4.7.2. Marketing Strategy
        • 18.3.4.7.3. Product Strategy
    • 18.3.5. Aspen
      • 18.3.5.1. Overview
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Key Financials
      • 18.3.5.4. Geographical Footprint
      • 18.3.5.5. SWOT Analysis
      • 18.3.5.6. Key Developments
      • 18.3.5.7. Strategy Overview
        • 18.3.5.7.1. Channel Strategy
        • 18.3.5.7.2. Marketing Strategy
        • 18.3.5.7.3. Product Strategy
    • 18.3.6. Mylan (Viatris)
      • 18.3.6.1. Overview
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Key Financials
      • 18.3.6.4. Geographical Footprint
      • 18.3.6.5. SWOT Analysis
      • 18.3.6.6. Key Developments
      • 18.3.6.7. Strategy Overview
        • 18.3.6.7.1. Channel Strategy
        • 18.3.6.7.2. Marketing Strategy
        • 18.3.6.7.3. Product Strategy

19. Assumptions and Acronyms Used

20. Research Methodology